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Abstract
Backgrounds: Urokinase (UK) 2 200 U/kg·h for 12 hours infusion(UK-12 h)is an ACCP recommended regimen
in treating acute pulmonary embolism (PE). It is unclear whether this dose and time can be reduced further. We
compared the efficacy and safety of 20, 000 U/kg for 2 hours (UK-2 h) with the UK-12 h regime in selected PE
patients.
Methods: A randomized trial involving 129 patients was conducted. Patients with acute PE were randomly
assigned to receive either UK-12 h (n = 70), or UK-2 h (n = 59). The efficacy was determined by the improvement
of right heart dysfunction and perfusion defect at 24 h and 14 d post UK treatment. The bleeding incidence, death
rate and PE recurrence were also evaluated.
Results: Similarly significant improvements in right heart dysfunction and lung perfusion defects were observed
in both groups. Overall bleeding incidents were low in both groups. Major bleeding directly associated with UK
infusion occurred in one patient in the UK-2 h group and one in the UK-12 h group. Mortality rates were low,
with one reported fatal recurrent in the UK-12 h group and none in the UK-2 h group. When the rate of bleeding,
death and PE recurrence were compared separately in the hemodynamic instability and the massive anatomic
obstruction subgroups, no significant difference was found.
Conclusions: The UK-2 h regimen exhibits similar efficacy and safety as the UK-12 h regimen for acute PE.
Trial Registration: Clinical trial registered with http://clinicaltrials.gov/ct2/show/NCT00799968 (Identifier:
NCT 00799968)
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Background
Urokinase (UK) can produce mild and prolonged throm-
bolytic state with minimal disturbance of blood coagula-
tion. Its effect is highly controllable when administered at
body weight adjusted dosages [1,2]. Additionally, UK is
much cheaper than tissue plasminogen activator (rt-PA).
The reliable efficacy and safety, as well as the low cost have
made UK a valuable agent in pulmonary embolism (PE)
thrombolytic therapy, and it is widely used in developing
countries.
Currently, no single UK regimen has been shown to be
superior over another in treating PE. A loading dose of
4400 IU/kg followed by 2200 IU/kg/hour for 12 hours
(UK-12 h) is recommended for acute PE treatment by
American College of Chest Physician (ACCP) guide-
line[3]. However, earlier studies have showed that the
bleeding incidence of this regimen was high [4,5]. Reduc-
ing infusion time to 2-h have demonstrated promising
results with decreased major bleeding rate. Additionally,
we have observed that the UK-2 h (20 000 U/kg over 2 h)
regime has superior thrombolytic effects over the UK-12 h
regimen for fresh thrombi in a canine PE model [6].
Because of the potential advantages of lower bleeding risk,
increased effectiveness for fresh thrombi, convenience
and lower cost, UK-2 h becomes a promising regimen.
However, there is no direct comparison between this reg-
imen with the ACCP recommended UK12 h regimen.
In this study, we compared UK2 h and UK-12 h regimen
in treating acute PE in a randomized, controlled, multi-
center trial. Acute PE patients with either haemodynamic
instability/cardiogenic shock [7,8] or anatomic massive
obstruction and right ventricular dysfunction(RVD) were
enrolled in the study. Efficacy was assessed by the
improvements in right ventricular (RV) function, the pul-
monary perfusion on V/Q scan and pulmonary artery
obstruction on CT pulmonary angiograms (CTPA) at 24 h
and 14 d after treatment. Safety was evaluated by the inci-
dence of bleeding, PE recurrence and death rates.
Methods
Study Organization
A prospective, randomized, open label, multi-center trial
was conducted between July 2002 and February 2006 in
China. The trial was suspended for nearly one year due to
the severe acute respiratory syndrome (SARS) outbreak in
2003. A central steering committee was formed in charge
of study design, protocol development and standardiza-
tion, quality control, data verification and analysis. The
study protocols were reviewed and approved by institu-
tional boards and ethics committees of all participating
centers. Patients enrolled in the study were centrally ran-
domly assigned to the treatment group with a standard
computerized randomization program. The clinical infor-
mation and images of each patient were reviewed inde-
pendently by the members of the steering committee.
Patient Selection
Patients aged 18 to 75 years with acute PE (symptoms that
occurred within 15 days at time of enrollment) were
screened. All diagnoses were confirmed either by a high
probability V/Q scan or by the presence of intraluminal
filling defect on spiral CTPA. The indication for thrombo-
lytic therapy was: (1) patients with haemodynamic insta-
bility or cardiogenic shock; (2) patients with massive
pulmonary artery obstruction (obstructions in more than
2 lobes on CTPA, or perfusion defects in more than 7 seg-
ments on V/Q scan) and combined right ventricular dys-
function (RVD) and pulmonary hypertension on
echocardiographic examination. Studies have shown that
these patients are at high risk of fatal conditions and may
benefit from thrombolytic therapy[9-11]. Patients were
excluded if they had received parenteral heparin for more
than 72 hours or had thrombolytic contraindications.
Written informed consents were obtained from all the
patients.
Treatment regimens
Eligible subjects were randomly assigned into either the
UK-12 h group (bolus 4 400 U/kg followed by intrave-
nous 2 200 U/kg·h for 12 hours) or UK-2 h group (20 000
U/kg intravenous infusion for 2 hours) (Figure 1). Rand-
omization was performed on a central control manner
according to a standard randomization program. UK used
in this study was from Guangzhou Techpool (Bio Pharma
Co Ltd, China).
After UK infusion, the activated partial thromboplastin
time (aPTT) was tested. If the value was less than 80 sec, a
subcutaneous injection of low molecular weight heparin
(nadroparin, 86 anti-factor Xa IU/kg) was given every 12
hours. Overlapping oral anticoagulant therapy (warfarin)
was started on day 1-3 after nadroparin injection to main-
tain an international normalized ratio (INR) of 2.0 to 3.0.
Nadroparin was stopped 4-5 days after warfarin was
added and INR was stabilized at 2.0 to 3.0 for at least 2
days. Warfarin was continuously used for at least 3-6
months, and subsequent doses were adjusted to maintain
the INR at within 2.0-3.0 range, targeting value 2.5.
Efficacy
Symptoms and signs of PE in all patients were monitored.
Echocardiogram, V/Q lung scan and CTPA were evaluated
within 48 hours before UK infusion, and repeated in most
patients at 24 h and 14 d after UK treatment. Efficacy was
determined by the improvements of right ventricular
functions on echocardiogram, the lung perfusion on lung
V/Q scans and pulmonary artery obstruction on CTPA.Respiratory Research 2009, 10:128 http://respiratory-research.com/content/10/1/128
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Echocardiograms
Echocardiograms were performed and analyzed by two
echocardiographers. Right ventricular function was ana-
lyzed by the improvement of (1) right and left ventricular
end-diastolic diameter ratio in the parasternal long-axis
view (RVED/LVED); (2) right/left ventricular dimension
ratio (RV/LV dimension); (3) estimated systolic pulmo-
nary artery pressure (SPAP), in the absence of left ventricu-
lar disease or mitral valve disease as previously
reported[10,11]. SPAP was measured using the following
equation: SPAP was 4 × (VTR)2 + right atrial pressure
(RAP). RAP was estimated according to the respiratory
motion of IVC.
V/Q lung scan
Lung scans were independently reviewed and evaluated
by two specialists using the methods described previously
[12,13]. Each anatomic segment of the lung was reviewed
and the defect within each segment was scored according
to the level of perfusion reduction.
CTPA
The location and severity of thrombus obstruction of the
pulmonary vascular bed were reviewed and evaluated by
helical CTPA score system described in previous studies
[14,15]. The index is defined as the product N × D, where
N is the value of the proximal clot site (equal to the
number of segmental branches arising distally) and D is
the degree of obstruction. Partial obstruction is scored as
1 and total obstruction is graded as 2.
Death, bleeding and pulmonary embolism recurrence
Adverse events were monitored for 14 days after initial
treatment with UK. Deaths were classified as being due to
PE, bleeding, or other causes (including myocardial inf-
arction and unknown causes). Major bleeding included
fatal bleeding, intracranial hemorrhage (ICH), or a drop
in the hemoglobin concentration by at least 20 g/L, or
required transfusion of more than 400 ml red blood cell
(within 72 h of initiating UK therapy). Minor bleeding
included the bleeding with hemoglobin concentration
drop of less than 20 g/L. Recurrence of PE was confirmed
by V/Q scanning and/or spiral CTPA. Blood urea nitro-
gen(BUN) and creatinine(Cr) were monitored during the
whole interval of the study. The methods of kidney pro-
tection include encouraging patients to drink abundantly
or recommending the ward to ensure adequate hydration
to patients for 12 hours.
Statistical analysis
Calculation of sample size demonstrated that 110 patients
were required to show a difference of 10 points between
treatment groups in percent reduction of the score of
CTPA at 24 h from the onset of thrombolysis with 80%
Study flow diagram Figure 1
Study flow diagram.
Assessed for eligibility (n=137)
Excluded (n=8)
Lack of consent (n=2)
Work overload (n=1)
Decision of attendant clinician (n=3)
Undisclosed reason (n=2)
Enrolled (n=129)
Randomized to UK-12h group (n=70)
Received UK-12h regimen (n=70)
Randomized to UK-2h group (n=59)
Received UK-2h regimen (n=59)
Follow up through the end of study (n=69)
Lost to follow up (n=1)
Follow up through the end of study (n=55)
Lost to follow up (n=4)
Included in the efficacy analysis (n=70)
Included in the safety analysis (n=70)
Included in the efficacy analysis (n=59)
Included in the safety analysis (n=59)
Patient enrollment, randomization and follow upRespiratory Research 2009, 10:128 http://respiratory-research.com/content/10/1/128
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power and a two-sided level of significance of 0.05,
assuming a standard deviation of 10 points. Data were
analyzed according to the intention-to-treat principle.
Categorial data were compared using chi-square test and
Fisher's test (2 × 2 table). Comparison of continuous data
between the treatment groups were performed using t test
or the Willcoxon test as appropriate. Changes in the meas-
urements of Echocardiograms, V/Q scan, and CTPA over
time were analyzed using repeated measures analysis of
variance. Subgroup analysis was also conducted base on
the homodynamic status of massive PE. All reported P val-
ues are 2-sided. P < 0.05 was statistically significant. A
post hoc subgroup analysis was also conducted base on
the homodynamic status of massive PE by using unpaired
t test, chi-square test or Fisher's test as appropriate.
Results
Patient population and baseline characteristics
137 patients with acute PE were preselected in the partici-
pating centers. 125 patients were confirmed with CTPA.
98 patients were evaluated with V/Q at the same time. 8
(7%) were ineligible because of the predefined exclusion
criteria. Among the 129 enrolled in this study, 70 were
assigned to UK-12 h and 59 were assigned to UK-2 h(Fig-
ure 1). There were no significant differences between the
two groups in baseline characteristics (Table 1).
Efficacy
The improvements of pulmonary artery pressure and RV
function were evaluated by echocardiograms. The base-
line, 24 h and 14 d follow-up evaluations of RVED/LVED
ratio, RV/LV dimension ratio and SPAP were performed in
96 (74%) patients, 51 in the UK-12 h group and 45 in the
UK-2 h group. Both treatment groups showed signifi-
cantly progressive improvements of right ventricular func-
tions determined by all three measurements. No
significant difference was found between the two treat-
ment groups in these measurements at different time
points (Figure 2A).
Improvement of lung perfusion was determined by V/Q
lung scan. The baseline, 24 h and 14 d follow-up V/Q lung
scans were conducted in 88 (68%) patients, 48 in the UK-
12 h and 40 in the UK-2 h group. Both treatments
achieved significant improvements in pulmonary vascular
perfusion defects, with similar scores at 24 h and 14 d post
rt-PA administration (Figure 2B).
The improvement of pulmonary artery obstruction was
assessed by CTPA. 125 patients (96%) underwent base-
line, 24 h and 14 d follow up CTPAs, 70 in the UK 12 h
group and 55 in the UK 2 h group. Quantitative assess-
ment showed that the two treatment groups had substan-
tial reductions in PE obstructive index at different time
points after treatment, with no significant difference
between the groups (Figure 2C).
The distributions of significant improvement, slight
improvement, no change and worse were similar between
the two regimens (Table 2).
Table 1: Baseline characteristics
Characteristics UK-12 h (n = 70) UK-2 h (n = 59)
Gender (male/female) 41/29 37/22
Age mean ± SD (y) 55.1 ± 16.1 56.5 ± 14.1
Weight mean ± SD (kg) 67.7 ± 11.9 68.2 ± 10.4
BMI mean ± SD(kg/m2) 24.4 ± 4.2 24.6 ± 3.5
Prior DVT or PE, n (%) 3(4.3) 5(8.6)
CVD, n (%) 8(11.4) 7(12.1)
Hypertension, n (%) 17(24.3) 18(31.0)
Diabetes mellitus, n (%) 6(8.6) 4(6.9)
COPD, n (%) 4(5.7) 5(8.6)
Malignancy, n (%) 2(2.9) 3(5.2)
Systolic blood pressure mean ± SD (mmHg) 127.0 ± 21.0 121.8 ± 17.0
Diastolic blood pressure mean ± SD (mmHg) 80.9 ± 12.3 74.2 ± 13.9
PaO2 (mmHg) 72.9 ± 20.3 70.8 ± 16.5
PaCO2 (mmHg) 34.5 ± 5.9 33.8 ± 6.6
Respiratory rate mean ± SD (rpm) 23.1 ± 4.9 23.7 ± 6.4
Heart rate mean ± SD (bpm) 96.4 ± 17.6 93.9 ± 17.8
Hb mean ± SD (g/L) 128.9 ± 22.3 125.7 ± 20.8
Hemodynamically massive PE*, n (%) 20 (28.6) 20 (33.9)
Anatomically massive PE with RVD & PH¶, n (%) 50(71.4) 39 (66.1)
* Arterial hypotension (a systolic arterial pressure <90 mm Hg or a drop in systolic arterial pressure of at least 40 mm Hg for at least 15 minutes) 
or cardiogenic shock.
¶ Pulmonary artery obstruction > 2 lobes on CTPA or >7 segments on V/Q scan combined with RVD and PH, but without hypotension or 
cardiogenic shock.Respiratory Research 2009, 10:128 http://respiratory-research.com/content/10/1/128
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Mortality, bleeding, and pulmonary embolism recurrence
The mortality rate was low in both groups. One patient
(1.4%) in the UK-12 h group died of recurrent PE. Two
(3.4%) patients in the UK-2 h group died, one died at 25
minutes after the initiation of UK due to PE combined
with respiratory and congestive heart failure, and the
other one died 3 days after the initiation of the treatment
due to acute myocardial infarction.
The incidence of overall bleeding in the two groups was
similar (13.6% in UK-2 h group vs. 14.3% in UK-12 h
group). The incidences of major bleeding and minor
bleeding were also similar in the two groups. No intracra-
nial bleeding episode was found in either group. No fatal
bleeding episode was reported in either group. It is impor-
tant to emphasize that the majority of major bleeding
occurred 3 days after UK infusion. Only one patient with
major bleeding episodes in UK 2 h group and one patient
in UK 12 h group were directly associated with UK
(occurred with 72 hours after initiation of UK).
One fatal recurrent PE was reported at 4 days post-treat-
ment in the UK-12 h group. No other episode of recurrent
symptomatic PE was reported in either group (Table 3).
Efficacy and safety in patients with hemodynamic 
instability or massive pulmonary artery obstruction
Further subgroup comparisons were conducted separately
in patients with hemodynamic instability and in patients
with massive pulmonary artery obstruction. In patient
with hemodynamic instability, UK-12 h and UK-2 h pro-
duced similar progressive improvements in pulmonary
artery obstructions (Table 4). Additionally, no difference
was found between these two treatments in terms of
death, bleeding, and PE recurrence in these patients. Sim-
ilarly, these two treatments showed similar efficacy and
Comparison of right heart functions (A), lung perfusion defect scores (B) and pulmonary artery obstruction scores (C)  between the two treatments (Data are presented with mean ± SE) Figure 2
Comparison of right heart functions (A), lung perfusion defect scores (B) and pulmonary artery obstruction 
scores (C) between the two treatments (Data are presented with mean ± SE).
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safety in patients with massive pulmonary vascular
obstruction combined with RVD.
Discussion
Our study showed that the UK-2 h regimen exhibited sim-
ilar efficacy as the UK-12 h regimen in PE thrombolytic
therapy, with similar progressive improvements in pul-
monary perfusion defects and RVD during the 14 d post-
treatment period. The two regimens had similar bleeding
incidences and death rates.
Thrombolytic efficacy
Previous studies have demonstrated that UK12 h and UK
24 h can induce a rapid thrombolysis in pulmonary circu-
lation in acute massive PE [16,17]. Increasing evidence
suggests that UK infusion dosage and duration can be
reduced further. It has been shown that 3 million IU UK
infusion over 2 h followed by heparin therapy is as effec-
tive and safe as the rt-PA 100 mg over 2 h regimen [18,19].
A much lower dose of 20 000 IU/kg UK over 2 h has been
shown to be effective without severe bleeding and allergic
reaction [20]. In this study, we demonstrated that UK-2 h
regimen, a much lower dose (20 000 IU/kg) than those
used in previous trials (3 million IU/2 h)[18,19], pro-
duced similar improvements in pulmonary circulation
and right heart dysfunction as the UK-12 h regimen. In
our practice, we use thrombolytic therapy instead of anti-
coagulation therapy alone to treat patients with extensive
pulmonary artery obstruction (defined as an obstruction
exceeding 50% of the pulmonary vasculature or the occlu-
sion of two or more lobar arteries)[21,22], combined with
echocardiographic signs of RV overload. Even presented
with normal systemic arterial pressure, these patients are
at risk of deteriorating conditions and have worse progno-
sis [23,24]. Studies have shown that these patients may
benefit from thrombolytic therapy [25,26]. The current
guideline also suggests that thrombolytic therapy may be
considered in selected patients with intermediate risk PE
after thorough consideration of conditions increasing the
risk of bleeding[3,27]. In this study, we therefore included
these patients.
The subgroup analysis in our present paper was not pre-
defined in the protocol. As a result, we did not have
Table 2: Comparison of the pulmonary artery obstruction improvement scales between the two treatments
24 hour 14 day
Qualitative Change UK-12 h
(n = 70)
UK-2 h
(n = 55)
P UK-12 h
(n = 70)
UK-2 h
(n = 55)
P
Significant improvement 34(48.6) 36(61.1) 0.373 47(67.1) 44(74.6) 0.807
Slight-improvement 16(22.9) 11(18.6) 17(24.3) 12(20.3)
No change 8(11.4) 8(13.6) 3(4.3) 2(3.4)
Worse 12(17.1) 4(6.8) 3(4.3) 1(1.7)
Any improvement* 50(71.4) 47(79.7) 0.281 64(91.4) 56(94.9) 0.439
Data presented are number (%) of patients.
The improvements of pulmonary artery obstruction from baseline between the two treatments were compared.
* Any improvement (%) = (significant + slight)/total, which indicates the percentage of overall improvement. Significant improvement- obstruction 
decreased by ≥ 75%; slight improvement - obstruction decreased by ≥ 25% but < 75%; no change - obstruction reduced by < 25%; worse - 
obstruction increased in score index.
Table 3: Comparison of adverse events during the first 14 days after treatment between the two treatments
Adverse events UK-12 h(n = 70) UK-2 h(n = 59) P
Death 1(1.4) 2(3.4)
Due to PE 1(1.4) 1(1.7) 0.462
Due to Bleeding 0(0) 0(0)
Due to Other Comordities 0(0) 1(1.7)
Recurrent PE 1(1.4) 0(0) 0.858
Fatal 1(1.4) 0(0)
Non fatal 0(0) 0(0)
Bleeding complications 10(14.3) 8(13.6) 0.332
Major bleeding 4(5.7) 6(10.2)
Fatal bleeding 0(0) 0(0)
Others 4(5.7) 6(10.2)
Minor Bleeding 6(8.6) 2(3.4)
Data presented are number (%) of patients.Respiratory Research 2009, 10:128 http://respiratory-research.com/content/10/1/128
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enough power to draw the conclusive data. Although this
inclusion may potentially make our efficacy comparison
of the two regimens less conclusive, subgroup analysis did
show that UK-2 h regimen was effective not only for
patients with intermediate risk PE but also for patients
with hemodynamic instability. Nevertheless, future stud-
ies with anticoagulation control in patients with interme-
diate risk PE will be valuable to determine whether
thrombolytic therapy is indeed beneficial in these
patients. Currently, giving LMWH is not a routine practice
for high risk PE patients. However, subcutaneous injec-
tion of LMWH has been shown to produce greater effi-
cacy, less hemorrhagic risk, and improved convenience in
clinical research and practice. Considering its advantages,
it would be safe to use LMWH in high risk PE patients after
thrombolytic therapy.
Adverse events
The mortality rates in our study (1.4-3.4%) were compa-
rable to those reported in previous clinical trials.
Although 2 (3.4%) patients in the UK-2 h group died,
both these two patients died in the early stage due to the
severity of disease it self and commodities. The patient's
death in the UK-12 h group was due recurrent PE.
The major bleeding rate in our study (5.7-10.2%) was
comparable to previously reported trials [19,27,28] and
the overall bleeding rate (13.6-14.3%) in our patients was
lower than that in the UKEP study (24-29%)[29]. The
high incidence of hemorrhagic complications observed in
early studies was mainly attributed to the invasive proce-
dures for angiographic and hemodynamic measurements
[19,27,29]. No allergic reactions were observed in our
study.
One major criteria in evaluating thrombolytic therapy is
recurrence of embolism, most of which occur during the
first week of follow-up and can result in a high mortality
rate. The recurrence in our study was similarly low in both
groups, with one patient in the UK-12 h group died of
recurrent PE at day 4 after initial treatment. No recurrent
PE was reported in UK-2 h group. Early thrombolytic ther-
apy may reduce the incidence of recurrence of embolism.
Further studies with prolonged observation are desirable
to compare the recurrence between these two different
regimens.
Study limitations
There are a few limitations in our study. Firstly, the
smaller sample size, a common limitation for PE throm-
bolytic studies, had prevented us from achieving more
powerful efficacy and safety analysis. This is particularly
true for smaller sample size for subgroup comparisons of
efficacy and the adverse events between the two treat-
ments in hemodynamically and anatomically massive PE
subgroups. Therefore, we could not draw a confirmed
conclusion. Further studies with larger sample size are
desirable to determine the efficacy and safety of this UK 2
h regimen. There is a serious imbalance in the number of
patients between the two treatment groups which was
attributable to smaller case numbers assigned to 2-hour vs
12-hour UK infusion. Larger sample size and centralized
Table 4: Comparison of efficacy and the adverse events between the two treatments in hemodynamically and anatomically massive PE 
subgroups
Hemodynamically massive PE Anatomically massive PE
UK 12 h
(n = 20)
UK 2 h
(n = 20)
pU K  12 h
(n = 50)
UK 2 h
(n = 39)
p
Efficacy
Pulmonary artery obstruction score by CTPA*
Baseline 16.1 ± 7.7 17.3 ± 10.5 0.670 13.7 ± 7.2 14.7 ± 7.6 0.523
24 -hour 13.1 ± 7.7 13.5 ± 11.7 0.899 10.5 ± 6.9 10.9 ± 8.1 0.783
14- day 6.9 ± 7.3 5.2 ± 9.8 0.527 4.5 ± 5.2 3.7 ± 4.6 0.452
Adverse events
Death 0 (0) 2 (10.0) 0.487 1(2)**** 0(0) 1.000
Due to PE 0(0) 1 (5.0)** 0 (0) 0(0)
Due to other reason 0(0) 1 (5.0)*** 0 (0) 0(0)
Due to Bleeding 0 (0) 0(0) 0 (0) 0(0)
Recurrent PE 0 (0) 0(0) 1(2) 0(0)
Bleeding complications 3(15) 3(15) 1.000 7(14) 5(13) 1.000
Major bleeding 1 (5.0) 3 (15.0) 0.605 3 (6) 3 (7.7) 1.000
Fatal bleeding 0 (0) 0(0) 0(0) 0(0)
Other 1 (5.0) 3 (15.0) 3(6) 3 (7.7)
Minor bleeding 2(10.0) 0(0.0) 0.487 4(8) 2(5.1) 0.692
* CT pulmonary angiographic assessment, Data presented are number (%) of patients.**The patient died due to the severity of PE. *** The patient 
died due to the commodities of acute myocardial infarction. **** The patient died due to recurrent PE.Respiratory Research 2009, 10:128 http://respiratory-research.com/content/10/1/128
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randomization should avoid this type of imbalance to
some extent.
Secondly, for the patients with extensive pulmonary artery
obstruction and RV dysfunction, a control group with
heparin alone was not included. Future studies with anti-
coagulation control will be valuable to determine whether
thrombolytic therapy is indeed beneficial in these
patients. The PEITHO (Pulmonary EmbolIsm THrOmbol-
ysis) study [30] is on going to determine whether throm-
bolysis can improve the outcome of patients presenting
with high-risk submassive acute PE compared with antico-
agulant alone, which will demonstrate the clinical bene-
fits of tenecteplase over placebo in normotensive patients
with acute PE and right ventricular dysfunction. Few ran-
domized trials have assessed the potential long-term ben-
efits of thrombolytic therapy in acute massive PE except
the study reported by Meneveau et al [31]. The study sug-
gested that a 2-h regimen of streptokinase can be routinely
used in patients with massive PE and maintained cardiac
output without obviously compromising efficacy or
safety. The long-term follow-up study would provide
more valuable information on thrombolytic therapy.
Conclusions
In conclusion, our study demonstrated that UK-2 h (20
000 IU/Kg) regimen displayed similar efficacy and safety
as the UK-12 h regimen in treating acute PE with either
hemodynamic instability or massive pulmonary artery
obstruction. Given the convenience, lower cost and the
similar efficacy and safety as the UK-12 h regime, we sug-
gest that body weight adjusted UK-2 h regimen could be
used for PE treatment. Further studies are required to eval-
uate the short and long-term outcomes of these different
UK thrombolytic regimens.
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